PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
ExpoCart is a marketplace that helps businesses in easily hiring and buying furniture, printed displays, floor coverings and more for exhibitions and events by a chain of suppliers. The company has built a customer base of 3500+ companies from 75+ countries. It has a strong supplier network and connections formed with a range of UK event and exhibition suppliers and, it has received a score of 8.5 on TrustPilot. The funds will be used to accelerate product range, strengthen the digital marketing channels and launch new technological platform features.
days to go:
Expired
investment:
£269,841
A current account for small business owners and the self-employed that automates their accounting and taxes. Coconut informs customers about transactions on their account that that are eligible for a tax deduction and automatically completes a tax return. It also provides a tax bill forecast and shows guidance on tax rules and regulations. Coconut currently looks after 3,000 accounts and has pre-registered 5,000 limited companies with total transactions processed exceeding £12m.
days to go:
Expired
investment:
£1,857,450
Yapa® is a free social app with an emphasis on your mental health. The application gives a solution to the users to have accurate changes in both mental illness and mental wellness. The application has exceeded 10,000 downloads, and it has 400,000 followers. It has elected former England and Liverpool FC goalkeeper Chris Kirkland as the first ambassador to encourage and build Yapa. The funds will be used for marketing, operation and product innovation.
days to go:
Expired
investment:
£41,930
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go:
Expired
investment:
£165,627
Hitmarker is a proprietary job platform that covers the entire video game sector. It aims to be the leading job provider in the $159 billion video game industry. It has a database of 67,000 candidates and has posted 46,000 jobs from 4,500 companies in 77 countries. The company asserts that one million people have used Hitmarker 2.5 million times to post or look for jobs. Hitmarker has been covered by publications like Forbes, CNBC, and The FT. It has also onboarded 20 partners, including The University of California, RGF Executive Search, and the British Esports Association. The company will use the investment to build a global network of localised platforms in crucial territories and expand its addressable market.
days to go:
Expired
investment:
£521,283
OvuSense is a women's health monitoring platform offering continuous insights into the reproductive cycle. With over 45,000 users and 10 patents, they aim to expand through partnerships, starting with a large IVF clinic chain. Addressing underdiagnosed health issues, their platform provides accurate cycle monitoring, health screening, and treatment tracking. Backed by institutional investors, OvuSense stands out for its predictive capabilities and accuracy in ovulation tracking, empowering women's fertility control.
days to go:
Expired
investment:
£169,920
